Drug Safety (2022) 45:191–192
https://doi.org/10.1007/s40264-021-01130-7

CORRECTION

Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy

John W. Day[1] · Jerry R. Mendell[2,3,4] · Eugenio Mercuri[5,6] · Richard S. Finkel[7,8] · Kevin A. Strauss[9,10,11,12] · Aaron Kleyn[13] · Sitra Tauscher-Wisniewski[13] · Francis Fonyuy Tukov[13] · Sandra P. Reyna[13] · Deepa H. Chand[13,14]

Published online: 23 December 2021

Correction to: Drug Safety (2021) 44:1109–1119
https://doi.org/10.1007/s40264-021-01107-6

In the original publication of the article, footnote marker 'b' was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.

Table 4 Hepatotoxicity adverse events and laboratory findings

Hepatotoxicity	START ($N = 15$)	STR1VE-EU ($N = 33$)	STR1VE-US ($N = 22$)	SPR1NT ($N = 30$)	STR1VE-AP ($N = 2$)	Total ($N = 102$)
Reported AEs	4 (26.7%)	18 (54.5)	7 (31.8)	8 (26.7)[a]	0	37 (36.3)
Elevations in LFT results (not reported as AEs)	10 (66.7)	12 (36.4)	13 (59.1)	19 (63.3)	1	54 (52.9)
Postdosing elevations in LFT results	15 (100)	29 (87.9)	20 (90.9)	26 (86.7)	0	90 (90.0)
Elevations in LFT results at baseline (prior to dosing)[b]	9 (60.0)	22 (66.7)	5 (22.7)	20 (66.7)	0	56 (54.9)

AEs adverse events, *LFTs* liver function tests, *ULN* upper limit of normal

[a]One of these events did not have laboratory abnormalities that were reported

[b]LFTs included analysis of aspartate aminotransferase, alanine aminotransferase, and bilirubin; all were $< 2 \times$ ULN

The original article can be found online at https://doi.org/10.1007/s40264-021-01107-6.

✉ John W. Day
jwday@stanford.edu

1 Department of Neurology, Stanford University Medical Center, MC 5979, 213 Quarry Road, Palo Alto, CA 94304, USA

2 Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA

3 Department of Pediatrics, Ohio State University, Columbus, OH, USA

4 Department of Neurology, Ohio State University, Columbus, OH, USA

5 Department of Paediatric Neurology and Nemo Clinical Centre, Catholic University, Rome, Italy

6 Centro Clinico Nemo, Fondazione Policlinico Gemelli IRCCS, Rome, Italy

7 Department of Pediatrics, Nemours Children's Hospital, Orlando, FL, USA

8 Center for Experimental Neurotherapeutics, St. Jude's Children's Research Hospital, Memphis, TN, USA

9 Clinic for Special Children, Strasburg, PA, USA

10 Penn Medicine-Lancaster General Hospital, Lancaster, PA, USA

11 Department of Pediatrics, University of Massachusetts School of Medicine, Worcester, MA, USA

12 Department of Molecular, Cell & Cancer Biology, University of Massachusetts School of Medicine, Worcester, MA, USA

13 Novartis Gene Therapies, Inc., Bannockburn, IL, USA

14 Department of Pediatrics, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, MO, USA